MEGF9 prevents lipopolysaccharide-induced cardiac dysfunction through activating AMPK pathway
We for the first time demonstrate that MEGF9 prevents LPS-related inflammation, oxidative damage and cardiac injury through activating AMPK pathway, and provide a proof-of-concept for the treatment of LPS-induced cardiac dysfunction by targeting MEGF9.
Authors
- Ming Chen (ORCID: https://orcid.org/0009-0003-9835-9432)
- Wanli Jiang (ORCID: https://orcid.org/0009-0002-7389-9638)
- Zhibing Lu (ORCID: https://orcid.org/0000-0002-7950-3465)
- Di Fan (ORCID: https://orcid.org/0000-0002-7223-0345)
- Xiaoyan Wu
- Huixia Liu (ORCID: https://orcid.org/0009-0004-8577-196X)
- Hairong Wang (ORCID: https://orcid.org/0009-0003-6835-0998)
- Xianqing Li
- Tao He (ORCID: https://orcid.org/0000-0002-1074-2089)
- Zhili Jin
- Li Peng (ORCID: https://orcid.org/0009-0000-5017-1690)
- Yongzhen Fan
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Redox Report
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1080/13510002.2024.2435252
- Citations
- 3
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- Natural Science Foundation of Hubei Province
- Wuhan University
- Zhongnan Hospital of Wuhan University